Niowave, Inc.

Niowave, Inc., founded in 2005, is revolutionizing the production and distribution of medical and industrial radioisotopes, with a focus on accelerating the fight against cancer. The company's use of a superconducting linac instead of a nuclear reactor not only simplifies operations and reduces licensing costs, but also eliminates the need for a nuclear reactor and weapons-grade uranium. Its offerings include alpha, beta, and gamma sources, and the small batch radiochemistry operations can be automated, bypassing the need for licensing as a nuclear reprocessing facility. This innovative approach has attracted significant attention, with the latest milestone being a $500.00K grant investment received on April 11, 2023, from the Michigan Economic Development Corporation. Niowave operates in the Manufacturing and Pharmaceutical industries, with its headquarters based in the United States. By leveraging existing radiopharmaceutical supply chain and FDA approval processes, Niowave is streamlining isotope production and distribution, making strides in advancing cancer treatment and industrial applications.